Pharming Group (NASDAQ:PHAR) Reaches New 52-Week High - Still a Buy?

Pharming Group (NASDAQ:PHAR - Get Free Report) hit a new 52-week high on Monday . The company traded as high as $11.72 and last traded at $11.07, with a volume of 4600 shares trading hands. The stock had previously closed at $10.60.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PHAR shares. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer increased their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company has a 50 day moving average price of $9.19 and a 200 day moving average price of $8.99. The firm has a market cap of $812.36 million, a PE ratio of -45.93 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. Sell-side analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.